Irrespective of HER2 expression status, both tumor and stromal compartments of invasive breast cancers exhibit high levels of CTSL, which efficiently cleaves T-DXd’s specialized linker, enabling payload release and exerting cytotoxic effects against HER2-low or HER2-negative tumors[20]. Here, ERBB2 is linked to invasive breast carcinoma.